全文获取类型
收费全文 | 292篇 |
免费 | 13篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 45篇 |
妇产科学 | 6篇 |
基础医学 | 16篇 |
口腔科学 | 3篇 |
临床医学 | 34篇 |
内科学 | 71篇 |
皮肤病学 | 3篇 |
神经病学 | 8篇 |
特种医学 | 19篇 |
外科学 | 56篇 |
综合类 | 7篇 |
预防医学 | 7篇 |
眼科学 | 2篇 |
药学 | 11篇 |
肿瘤学 | 21篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 9篇 |
2020年 | 3篇 |
2019年 | 2篇 |
2018年 | 4篇 |
2017年 | 4篇 |
2015年 | 6篇 |
2014年 | 8篇 |
2013年 | 16篇 |
2012年 | 17篇 |
2011年 | 9篇 |
2010年 | 10篇 |
2009年 | 10篇 |
2008年 | 7篇 |
2007年 | 5篇 |
2006年 | 11篇 |
2005年 | 7篇 |
2004年 | 7篇 |
2003年 | 7篇 |
2002年 | 5篇 |
2001年 | 10篇 |
2000年 | 12篇 |
1999年 | 10篇 |
1998年 | 9篇 |
1997年 | 5篇 |
1996年 | 11篇 |
1995年 | 2篇 |
1994年 | 6篇 |
1993年 | 5篇 |
1992年 | 4篇 |
1991年 | 7篇 |
1990年 | 11篇 |
1989年 | 8篇 |
1988年 | 7篇 |
1987年 | 7篇 |
1986年 | 9篇 |
1985年 | 6篇 |
1984年 | 2篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1981年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1978年 | 4篇 |
1976年 | 1篇 |
1974年 | 1篇 |
1972年 | 1篇 |
1971年 | 4篇 |
1969年 | 1篇 |
排序方式: 共有309条查询结果,搜索用时 15 毫秒
81.
Donini CF Di Zazzo E Zuchegna C Di Domenico M D'Inzeo S Nicolussi A Avvedimento EV Coppa A Porcellini A 《International journal of oncology》2012,40(5):1627-1635
Phosphoinositide-3-OH kinase (PI3K) signalling regulates various cellular processes, including cell survival, growth, proliferation and motility, and is among the most frequently mutated pathways in cancer. Although the involvement of p85αPI3K SH2 domain in signal transduction has been extensively studied, the function of the SH3 domain at the N-terminus remains elusive. A serine (at codon 83) adjacent to the N-terminal SH3 domain in the PI3K regulatory subunit p85αPI3K that is phosphorylated by protein kinase A (PKA) in vivo and in vitro has been identified. Virtually all receptors binding p85αPI3K can cooperate with cAMP-PKA signals via phosphorylation of p85αPI3KSer83. To analyse the role of p85αPI3KSer83 in retinoic acid (RA) and cAMP signalling, in MCF7 cells, we used p85αPI3K mutated forms, in which Ser83 has been substituted with alanine (p85A) to prevent phosphorylation or with aspartic acid (p85D) to mimic the phosphorylated residue. We demonstrated that p85αPI3KSer83 is crucial for the synergistic enhancement of RARα/p85αPI3K binding induced by cAMP/RA co-treatment in MCF7 cells. Growth curves, colorimetric MTT assay and cell cycle analysis demonstrated that phosphorylation of p85αPI3KSer83 plays an important role in the control of MCF7 cell proliferation and in RA-induced inhibition of proliferation. Wound healing and transwell experiments demonstrated that p85αPI3KSer83 was also essential both for the control of migratory behaviour and for the reduction of motility induced by RA. This study points to p85αPI3KSer83 as the physical link between different pathways (cAMP-PKA, RA and FAK), and as an important regulator of MCF7 cell proliferation and migration. 相似文献
82.
83.
De Gregorio G Coppa A Cosentino C Ucci S Messina S Nicolussi A D'Inzeo S Di Pardo A Avvedimento EV Porcellini A 《Oncogene》2007,26(14):2039-2047
Phosphatidylinositol 3-kinase (PI3K) is necessary for thyroid stimulating hormone (TSH)-induced cell cycle progression. To determine the molecular mechanism linking PI3K to TSH, we have identified a serine residue in p85alpha(PI3K) phosphorylated by protein kinase A (PKA) in vitro and in vivo. Expression of an alanine mutant (p85A) abolished cyclic AMP/TSH-induced cell cycle progression and was lethal in thyroid cells (FRTL-5). The aspartic version of the p85alpha(PI3K) (p85D) inhibited apoptosis following TSH withdrawal. The p85alpha(PI3K) wild type not the p85A bound PKA regulatory subunit RIIbeta in cells stimulated with cAMP or TSH. The binding of the aspartic version of p85alpha(PI3K) to RIIbeta was independent of cAMP or TSH stimulation. Similarly, binding of PI3K to p21Ras and activation of AKT, a downstream PI3K target, were severely impaired in cells expressing the p85A mutant. Finally, we found that the catalytic activity of PI3K was stimulated by TSH in cells expressing the wild-type p85alpha(PI3K) but not in cells expressing p85A. This latter mutant did not affect the epidermal growth factor-stimulated PI3K activity. We suggest that (1) TSH-cAMP-induced PKA phosphorylates p85alpha(PI3K) at serine 83, (2) phosphorylated p85alpha(PI3K) binds RIIbeta-PKA and targets PKAII to the membrane, and (3) PI3K activity and p21Ras binding to PI3K increase and activate PI3K downstream targets. This pathway is essential for the transmission of TSH-cAMP growth signals. 相似文献
84.
L M Coppa M Alam B J Longley M J Stiller 《Cutis; cutaneous medicine for the practitioner》1999,64(4):243-244
We present a 66-year-old woman who developed eruptive keloids in association with endometrial carcinoma in the absence of trauma, surgery, inflammation, or other known preludes to keloid formation. Keloid formation and endometrial carcinoma are both associated with similar cytokine abnormalities and as such, we hypothesize that this is a previously unreported paraneoplastic phenomenon. 相似文献
85.
86.
87.
Natalie Prinzi Roberta Elisa Rossi Claudia Proto Giovanni Leuzzi Alessandra Raimondi Martina Torchio Massimo Milione Francesca Corti Elena Colombo Michele Prisciandaro Tommaso Cascella Carlo Spreafico Teresa Beninato Jorgelina Coppa Giuseppe Lo Russo Maria Di Bartolomeo Filippo de Braud Sara Pusceddu 《Clinical lung cancer》2021,22(3):161-169
Neuroendocrine neoplasms of the lung represent about 20% to 30% of all neuroendocrine tumors. On the basis of clinical and pathologic characteristics, 2 different categories of tumors may be defined: poorly differentiated neuroendocrine neoplasms, characterized by a high rate of recurrences and poor prognosis, and well-differentiated neuroendocrine neoplasms (typical carcinoids and atypical carcinoids), which generally display an indolent course. Lung carcinoids represent only 1% to 5% of all lung malignancies, but their incidence has significantly increased over the past 30 years. Surgery is the reference standard of treatment for lung carcinoids with locoregional disease. For advanced or unresectable lung carcinoids, several therapeutic options are available, but the choice should be shared within a multidisciplinary team to ensure optimal therapeutic outcomes. We describe the current management of these rare neoplasms. 相似文献
88.
89.
A R Bonfigli S Manfrini F Gregorio R Testa I Testa G De Sio G Coppa 《Therapeutic drug monitoring》1999,21(3):330-334
Metformin is an oral antihyperglycemic agent used in the therapy of noninsulin-dependent diabetic patients. This biguanide can induce dangerous complications such as lactic acidosis when its plasma concentration is too high. For this reason, the determination of plasma metformin should always be done during treatment. We developed a new HPLC method, for the routine determination of plasma metformin, with good reliability, rapid execution, and low costs. Sample preparation involved precipitation of the plasma proteins containing the internal standard buformin with a mixture of methanol, zinc sulfate, and ethylene glycol; the diluted supernatant was injected into a cation-exchange column. The mobile phase was potassium dihydrogenphosphate buffer-containing acetonitrile. The eluent was monitored at 236 nm. The calibration curve is linear within the range of 20-4000 ng/mL; the within-day coefficients of variation were less than 2.2% for metformin and 1.5% for buformin; the day-to-day coefficients of variation were less than 2.5% for metformin and 1.9% for buformin. The mean recoveries obtained from supplemented samples were included between 99.4 and 104.2% for metformin. Many characteristics make this method useful and easily accessible to all clinical laboratories equipped with HPLC instrumentation. 相似文献
90.